We are grateful to our partners for their support of the Nottingham Breast Pathology Online Masterclass
PathLAKE Digital Pathology courses for breast
A new suite of online educational modules for those looking to train and develop their skills in digital pathology and reporting are now available on the PathLAKE Digital Pathology Education Tutor platform.
The course demonstrates the utility of using a digital platform in the assessment of pathological features and is approved for 4 CPD points from the UK Royal College of Pathologists. Your Certificate of Participation could be included in a submission of evidence towards completion of stage 1 validation in digital pathology.
To request access, please email firstname.lastname@example.org
Exact Sciences is a leading provider of cancer screening and diagnostic tests. From earlier detection to treatment guidance, we are helping people get the answers they need to make more informed decisions.
Building on the success of the Oncotype DX® and Cologuard® tests, the company is investing in its product pipeline across all stages of the cancer journey. The Oncotype DX Breast Recurrence Score® test is the only genomic test validated for its ability to predict the likelihood of chemotherapy benefit as well as the risk of recurrence in early-stage breast cancer.
The test is designed to facilitate personalised clinical decisions by providing information about the biology of an individual breast cancer, with the potential to deliver financial benefits for healthcare systems. To date, the Oncotype DX® test has been used in more than one million patients worldwide to guide their treatment decisions.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
With its global headquarters in Cambridge, AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, we undertook 201 trials in the UK, involving 376 centres and over 7,000 patients.
For more information, please visit www.astrazeneca.co.uk and follow us at @AstraZenecaUK
Pathology Group specialise on the provision of Pathology doctors to the NHS and Ireland.
Having established our name as a professional and specialised consultancy, we are often given access to extremely desirable roles first and we endeavour to tailor for all needs.
We offer our doctors and departments a range of flexible contracts to meet every need; whether you are a substantive looking for ad-hoc or annual leave work to supplement your income, or a doctor looking for a long-term and stable contract, we can cater for you.